More British Columbians and people around the world will benefit from the life-changing work of B.C.’s world-renowned life sciences sector thanks to a significant investment in health research.
As announced in Budget 2022 and aligned with the StrongerBC Economic Plan commitment to position the province as a hub for life sciences and biomanufacturing, the Province is providing nearly $195 million in grant funding to Michael Smith Health Research BC (Health Research BC) and Genome BC.
“B.C. has so much to be proud of as we come through the last two years of the pandemic as a global leader in new health technologies, treatments and vaccines,” said Ravi Kahlon, Minister of Jobs, Economic Recovery and Innovation. “This new funding is a significant step to establishing a life sciences hub to support the sector’s growth and diversification and to anchor B.C. as a worldwide leader and developer of new talent, research capacity and life-changing innovation. Life sciences is a powerful sector that touches every part of our lives – from health to the environment to food security, natural resources and more. This is what our economic plan is all about – it’s about building a strong, sustainable province that works for everyone.”
The Province is investing $116.6 million in funding to Health Research BC and another $78 million to Genome BC. These grants will support research in health, agriculture, clean technology and climate change, while also strengthening B.C.’s pandemic and emergency preparedness. The grants will also help attract, develop and retain research talent and support job creation and health research employment and training in B.C.
“B.C.’s life sciences research and companies continue to receive international recognition for playing a key role in the development of new technologies and treatments,” said Adrian Dix, Minister of Health. “By expanding our investments here at home, we are ensuring our public health experts continue to receive world-class research to protect the health and safety of British Columbians while guaranteeing B.C. remains a global leader in research and innovation.”
Throughout the pandemic, B.C.’s life sciences research sector and businesses earned international recognition for their roles in developing new technologies, treatments and vaccines now used around the world. Virtually every COVID-19 vaccine candidate that reached late-stage development in 2020 used components developed or manufactured by a B.C. scientist or company.
“B.C. is in a stronger position to realize improved health through research thanks to a provincial budget that includes support for life sciences,” said Dr. Bev Holmes, president and CEO, Health Research BC. “We thank the provincial government for its continued support of Michael Smith Health Research BC and for recognizing that a healthy society and a healthy economy go hand in hand. This funding will help grow the knowledge economy and health research recovery as it will be used to attract, develop, support and retain people whose research improves the health of British Columbians, addresses health system priorities and creates jobs.”
As outlined as a key new action in the StrongerBC Economic Plan, B.C. will launch a Life Sciences and Biomanufacturing Strategy to position the province as a worldwide life sciences hub by nurturing new talent, developing new lab space, leveraging the research capacities of B.C.’s post-secondary sector and supporting employment across the sector.
“Thanks to the support of the provincial government, genomics will continue to support the rapid growth of B.C.’s life sciences sector,” said Dr. Pascal Spothelfer, president and CEO, Genome BC. “This investment will help impact change in healthcare, climate change, food security and beyond. With these funds, we will continue to support cutting-edge research and innovation, support future researchers, and demonstrate the relevance and value of genomics in delivering significant societal, environmental and economic benefits for the province.”
The StrongerBC Economic Plan moves British Columbia forward by tackling the challenges of today while growing an economy that works for everyone. The long-term plan builds off B.C.’s strong economic recovery and works to address two long-standing challenges – inequality and climate change – by closing the skills gap, building resilient communities, and helping businesses and people transition to clean-energy solutions. The plan sets two main goals for the province – inclusive growth and clean growth – and puts forward six missions to keep B.C. on track.
Quick Facts:
B.C. is home to the fastest-growing life sciences sector in Canada with more than 2,000 companies employing 18,000 British Columbians working on innovations and research to improve health-care delivery around the world.
Made-in-B.C. life sciences products include rapid diagnostic tests for diseases such as HIV/AIDS, hepatitis C and Ebola; protein therapeutics for treating cancer, autoimmune and inflammatory diseases; and the first FDA-approved oral medication for treating adult patients with active lupus nephritis.
B.C. is home to Canada’s largest biotech company, STEMCELL Technologies; Canada’s largest medical device company, Starfish Medical; and Canada’s three largest biotech companies, AbCellera Biologics, Aurinia Pharmaceuticals, and Zymeworks Inc.
TORONTO – Canada’s main stock index was down more than 200 points in late-morning trading, weighed down by losses in the technology, base metal and energy sectors, while U.S. stock markets also fell.
The S&P/TSX composite index was down 239.24 points at 22,749.04.
In New York, the Dow Jones industrial average was down 312.36 points at 40,443.39. The S&P 500 index was down 80.94 points at 5,422.47, while the Nasdaq composite was down 380.17 points at 16,747.49.
The Canadian dollar traded for 73.80 cents US compared with 74.00 cents US on Thursday.
The October crude oil contract was down US$1.07 at US$68.08 per barrel and the October natural gas contract was up less than a penny at US$2.26 per mmBTU.
The December gold contract was down US$2.10 at US$2,541.00 an ounce and the December copper contract was down four cents at US$4.10 a pound.
This report by The Canadian Press was first published Sept. 6, 2024.
TORONTO – Canada’s main stock index was up more than 150 points in late-morning trading, helped by strength in technology, financial and energy stocks, while U.S. stock markets also pushed higher.
The S&P/TSX composite index was up 171.41 points at 23,298.39.
In New York, the Dow Jones industrial average was up 278.37 points at 41,369.79. The S&P 500 index was up 38.17 points at 5,630.35, while the Nasdaq composite was up 177.15 points at 17,733.18.
The Canadian dollar traded for 74.19 cents US compared with 74.23 cents US on Wednesday.
The October crude oil contract was up US$1.75 at US$76.27 per barrel and the October natural gas contract was up less than a penny at US$2.10 per mmBTU.
The December gold contract was up US$18.70 at US$2,556.50 an ounce and the December copper contract was down less than a penny at US$4.22 a pound.
This report by The Canadian Press was first published Aug. 29, 2024.
The crypto market has recently experienced a significant downturn, mirroring broader risk asset sell-offs. Over the past week, Bitcoin’s price dropped by 24%, reaching $53,000, while Ethereum plummeted nearly a third to $2,340. Major altcoins also suffered, with Cardano down 27.7%, Solana 36.2%, Dogecoin 34.6%, XRP 23.1%, Shiba Inu 30.1%, and BNB 25.7%.
The severe downturn in the crypto market appears to be part of a broader flight to safety, triggered by disappointing economic data. A worse-than-expected unemployment report on Friday marked the beginning of a technical recession, as defined by the Sahm Rule. This rule identifies a recession when the three-month average unemployment rate rises by at least half a percentage point from its lowest point in the past year.
Friday’s figures met this threshold, signaling an abrupt economic downshift. Consequently, investors sought safer assets, leading to declines in major stock indices: the S&P 500 dropped 2%, the Nasdaq 2.5%, and the Dow 1.5%. This trend continued into Monday with further sell-offs overseas.
The crypto market’s rapid decline raises questions about its role as either a speculative asset or a hedge against inflation and recession. Despite hopes that crypto could act as a risk hedge, the recent crash suggests it remains a speculative investment.
Since the downturn, the crypto market has seen its largest three-day sell-off in nearly a year, losing over $500 billion in market value. According to CoinGlass data, this bloodbath wiped out more than $1 billion in leveraged positions within the last 24 hours, including $365 million in Bitcoin and $348 million in Ether.
Khushboo Khullar of Lightning Ventures, speaking to Bloomberg, argued that the crypto sell-off is part of a broader liquidity panic as traders rush to cover margin calls. Khullar views this as a temporary sell-off, presenting a potential buying opportunity.
Josh Gilbert, an eToro market analyst, supports Khullar’s perspective, suggesting that the expected Federal Reserve rate cuts could benefit crypto assets. “Crypto assets have sold off, but many investors will see an opportunity. We see Federal Reserve rate cuts, which are now likely to come sharper than expected, as hugely positive for crypto assets,” Gilbert told Coindesk.
Despite the recent volatility, crypto continues to make strides toward mainstream acceptance. Notably, Morgan Stanley will allow its advisors to offer Bitcoin ETFs starting Wednesday. This follows more than half a year after the introduction of the first Bitcoin ETF. The investment bank will enable over 15,000 of its financial advisors to sell BlackRock’s IBIT and Fidelity’s FBTC. This move is seen as a significant step toward the “mainstreamization” of crypto, given the lengthy regulatory and company processes in major investment banks.
The recent crypto market downturn highlights its volatility and the broader economic concerns affecting all risk assets. While some analysts see the current situation as a temporary sell-off and a buying opportunity, others caution against the speculative nature of crypto. As the market evolves, its role as a mainstream alternative asset continues to grow, marked by increasing institutional acceptance and new investment opportunities.
